To Evaluate SSD8432/ Ritonavir in Adults With COVID-19


This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.

Full Title of Study: “Randomized, Double-blind, Phase Ib Clinical Trial to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetic of SSD8432/ Ritonavir Multiple Doses in Treatment of Adults With Asymptomatic Infection, Mild, and Common Type of COVID-19”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 1, 2022

Detailed Description

This is a randomized, double-blinded, placebo-controlled, dose-climbing Phase Ib clinical trial, designed to evaluate the safety, pharmacodynamics, and pharmacokinetics of SSD8432/ ritonavir versus placebo in asymptomatic, mild, and common type adult COVID-19 subjects. This clinical trial is planned to enroll 32 asymptomatic infected, mild or common type adult COVID-19 subjects, divided into 2 cohorts according to different doses of SSD8432: Cohort 1: 16 subjects, 12 subjects will receive low-dose SSD8432/ ritonavir, and 4 subjects received placebo; Cohort 2: 16 subjects, 12 subjects will receive high-dose SSD8432/ ritonavir, and 4 subjects received placebo.


  • Drug: SSD8432 dose 1/Ritonavir
    • Cohort 1:SSD8432/ritonavir or placebo, on day 1 ~day5,BID;
  • Drug: SSD8432 dose 2/Ritonavir
    • Cohort 2:SSD8432/ritonavir or placebo, on day 1 ~day5,BID;

Arms, Groups and Cohorts

  • Experimental: SSD8432 dose 1
    • SSD8432 dose 1/ritonavir or placebo
  • Experimental: SSD8432 dose 2
    • SSD8432 dose 2/ritonavir or placebo

Clinical Trial Outcome Measures

Primary Measures

  • Adverse events
    • Time Frame: Baseline through Day 28
    • Frequency of TEAE

Secondary Measures

  • Viral load
    • Time Frame: Baseline through Day 28
    • Changes of viral load compared to the baseline
  • Time to Sustained Alleviation
    • Time Frame: Baseline through Day 28
    • Time to Sustained Alleviation of Targeted COVID-19 Signs/Symptoms
  • Proportion of Participants Progressing to a Worsening Status (higher score)
    • Time Frame: Baseline through Day 28
    • WHO clinical progression scale (0 to 10)
  • Maximum Plasma Concentration [Cmax]
    • Time Frame: Baseline through Day 5
    • Plasma Concentration of SSD8432
  • Area Under the Plasma concentration-time Curve [AUC]
    • Time Frame: Baseline through Day 5
    • Plasma Concentration of SSD8432

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥18 and ≤75, male or female. 2. Asymptomatic Infection, Mild, or Common Type of COVID-19. 3. Initial positive test of SARS-Cov-2 within 5 days of randomization. 4. Initial onset of COVID-19 signs/symptoms within 3 days of randomization. 5. The Ct value of SARS-COV-2 nucleic acid test before randomization is ≤ 25, or the Ct value is >25 and sarS-COV-2 serum IgG and IgM are negative. Exclusion Criteria:

1. Transnasal high-flow oxygen therapy or non-invasive ventilation, invasive mechanical ventilation, or ECMO is required or anticipated to be urgently required. 2. Prior to current disease episode, any confirmed SARS-CoV-2 infection. 3. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis). 4. Receiving dialysis or have known moderate to severe renal impairment. 5. Known human immunodeficiency virus (HIV) infection. 6. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.s. 7. Oxygen saturation of ≤ 93% on room air obtained at rest within 24 hours prior to randomization.. 8. Treatment with antivirals against SARS-CoV-2 within 14 days. 9. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance. 10. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days. 11. Has received or is expected to receive COVID-19 monoclonal antibody, convalescent COVID-19 plasma or other prohibited concomitant medication. 12. Females who are pregnant or breastfeeding.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jiangsu Simcere Pharmaceutical Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yumei Yang, Study Director, Jiangsu Xiansheng Pharmaceutical Co., LTD
  • Overall Contact(s)
    • Zhiqiang Lai, =86 025-85566666,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.